Rutgers Cancer Institute and RWJBarnabas Health Set to Unveil Extensive, New Cancer Research Findings at 2024 ASCO Annual Meeting
illi News/10267751

NEW BRUNSWICK, N.J., May 23, 2024 ~ At the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, clinicians and scientists from Rutgers Cancer Institute and RWJBarnabas Health will be leading sessions and presenting their latest discoveries from their innovative cancer research program. The meeting, which will be held in Chicago from May 30-June 4, will feature a total of 49 accepted abstracts and presentations covering cutting-edge topics in the field of oncology.

The team at Rutgers Cancer Institute and RWJBarnabas Health is renowned for their integrated network of researchers and clinicians who are dedicated to finding strategies that will achieve the best possible outcomes for cancer patients. According to Steven K. Libutti, MD, FACS, Director of Rutgers Cancer Institute and Senior Vice President of Oncology Services at RWJBarnabas Health, the dynamic lineup of presentations at this year's ASCO Annual Meeting reflects their commitment and dedication to advancing cancer research and care.

As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state, Rutgers Cancer Institute and RWJBarnabas Health are at the forefront of conquering a disease that impacts so many. They are eager to share their recent advancements and findings with the wider oncology community at this year's meeting.

More on illi News

• $430 Million 2026 Revenue Forecast; 26% Organic Growth; $500,000 Stock Dividend Highlight a Powerful AI & Digital Transformation Story: IQSTEL $IQST
• Wzzph Deploys 5-Million-TPS Trading Engine with Hot-Cold Wallet Architecture Serving 500,000 Active Users Across Latin America
• Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Dominate Raleigh's Best Awards from The News & Observer
• $73.6 Million Multi-Year Backlog and Florida State Term Contract Drive Momentum for AI-Cybersecurity Pioneer: Cycurion, Inc. (N A S D A Q: CYCU) $CYCU
• Year-Round Deals for Customers With Square Signs

The research accepted for presentation at ASCO includes one late-breaking abstract, as well as oral and poster sessions featuring data on various types of cancer such as breast, colorectal, lymphoma, and lung. One study that will be highlighted at the meeting examines how social vulnerability affects clinical trial enrollment among patients with breast, prostate, lung, colorectal or pancreatic cancer. The findings confirm that neighborhood social vulnerability is a barrier to trial enrollment, particularly among Black patients.

Another study focuses on enhanced recovery after surgery (ERAS) protocols for radical cystectomy. This study reviewed data from over 3,700 patients who underwent radical cystectomy and found that increased compliance with ERAS components was associated with improved postoperative recovery and shorter hospital stays.

Updates from a Phase 1/1b study investigating the AKT inhibitor ipatasertib in combination with chemoradiation therapy for locally advanced head and neck squamous cell carcinoma (HNSCC) will also be presented. This study aims to determine the maximum tolerated dose of ipatasertib in combination with definitive chemoradiation therapy for HNSCC.

More on illi News

• SecurePII Raises US$3.5M (A$5M) to Unlock AI and Compliance for Voice Data and Expands Global Presence
• The Data Diva Talks Privacy Podcast Celebrates Six Years, Nears One Million Downloads Globally
• Peter Coe Verbica Stands with Rural Families and Horse Owners: "Keep Horses Classified as Livestock"
• The Mobile-First Company Raises $12M to Build Simple, Powerful Software for Small Teams
• Lick Pineapple Flavored Massage Oil Outperforming and Enticing

Additionally, data from a Phase 3 clinical trial evaluating the efficacy and safety of odronextamab plus CHOP versus rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL) patients will be shared. The study, known as OLYMPIA-3, is comparing the two treatment regimens in patients with intermediate- or high-risk features of DLBCL.

Another interesting presentation will focus on a single institution pilot study, CIPHER, which evaluated whether circulating tumor DNA (ctDNA) testing during neoadjuvant therapy can serve as an early indicator of treatment response and inform disease management in the adjuvant setting. The study included 35 patients with stage II-III triple negative and HER2+ breast cancer who underwent longitudinal ctDNA testing during standard of care neoadjuvant therapy.

The full list of presentations at this year's ASCO Annual Meeting can be found on their website. With such a diverse range of topics being covered by Rutgers Cancer Institute and RWJBarnabas Health, it is clear that they are making significant contributions to the field of oncology and are dedicated to improving outcomes for cancer patients.

---

Show All News | Report Violation